37
Views
13
CrossRef citations to date
0
Altmetric
Original Articles

Switch to Efavirenz in a Protease Inhibitor-Containing Regimen

, , &
Pages 200-204 | Published online: 29 Jan 2015

REFERENCES

  • Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet. 1998;351:871–875.
  • Tachima KT, Horowitz JD, Rosen S. Indinavir nephropathy. N Engl J Med. 1997;336:138–140.
  • Hirsch M, Brun-Vézinet F, D'Aquila RT, et al. Antiretroviral drug resistance testing in adult HIV-1 infection. Recom-mendations of an International AIDS Society-USA Panel. JAMA. 2000.
  • Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med. 1999;341(25)1 865–1873.

SUGGESTED READING

  • Carr A, Cooper DA. A randomized, multicenter study of pro-tease inhibitor (P1) substitution in aviremic patients with antiretroviral (ARV) lipodystrophy syndrome. In: Programs and abstracts of the Seventh Conference on Retroviruses and Opportunistic Infections; January 30—February 2, 2000; San Francisco, CA. Abstract 205.
  • Carr A, Samaras K, Burton S. A syndrome of peripheral lipodys-trophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51—F58.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.